The Lancet Oncology最新文献

{"title":"New chemotherapy database to monitor ovarian cancer treatment in New Zealand","authors":"Manjulika Das","doi":"10.1016/s1470-2045(25)00274-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00274-8","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143897761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UK urged to support cancer research collaboration with EU","authors":"Sharmila Devi","doi":"10.1016/s1470-2045(25)00275-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00275-x","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143897759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Oncol 2025; 26: 200–13","authors":"","doi":"10.1016/s1470-2045(25)00210-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00210-4","url":null,"abstract":"<em>Wang M, Jurczak W, Trneny M, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.</em> Lancet Oncol <em>2025; <strong>26:</strong> 200–13</em>—In figure 2 of this Article, the data for age, splenomegaly, and extranodal disease were incorrect and have been amended. These corrections have been made to the online version as of April 30, 2025.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"136 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations in the meta-analysis of prostate radiotherapy-associated toxicity – Authors' reply","authors":"Amar U Kishan, Parsa Jamshidian, John Nikitas","doi":"10.1016/s1470-2045(25)00220-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00220-7","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complex cartography of cancer care","authors":"","doi":"10.1016/s1470-2045(25)00229-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00229-3","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Oncol 2025: published online April 14. https://doi.org/10.1016/S1470-2045(25)00150","authors":"","doi":"10.1016/s1470-2045(25)00238-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00238-4","url":null,"abstract":"<em>Pe M, Voltz-Girolt C, Bell J, et al. Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop.</em> Lancet Oncol <em>2025; published online April 14. https://doi.org/10.1016/S1470-2045(25)00150-0</em>—In this Essay, the affiliation of Jill Bell should have been Evinova an AstraZeneca Group, Gaithersburg, MD, USA only, and the affiliation of Jan Bogaerts should have been European Organisation for Research and Treatment of Cancer, Brussels, Belgium only. These corrections have been made to the online version as of April 30, 2025, and the printed version is correct.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond symbolism: embassies, equity, and the cancer equation","authors":"Paul Adepoju","doi":"10.1016/s1470-2045(25)00224-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00224-4","url":null,"abstract":"&lt;h2&gt;Section snippets&lt;/h2&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;From symbolism to systemic change&lt;/h2&gt;In Tanzania, a groundbreaking project is taking shape under the watchful eye of the US Embassy. The &lt;span&gt;&lt;span&gt;Kilimanjaro Christian Medical Centre&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, at the base of Africa's highest peak, is the site of a new cancer radiotherapy centre. It's a striking contrast: patients receiving cancer treatment in the shadow of the majestic Mount Kilimanjaro. This centre, built with funding from USAID, is a much-needed addition to a country where only two cancer centres serve over 62 million people. It promises not just&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Advocating for comprehensive health financing&lt;/h2&gt;One of the greatest challenges facing cancer care in Africa is the scarcity of funding. National health budgets in many countries prioritise infectious diseases, leaving non-communicable diseases such as cancer grossly underfunded. This situation is one in which embassies could wield their influence. By lobbying for increased allocations to health budgets, embassies can help ensure cancer care receives the attention it deserves.Imagine a Nigerian patient with cancer who travels hours from her&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Integrating cancer care into universal health coverage&lt;/h2&gt;Universal health coverage (UHC) has become a rallying cry for equitable health care, a vision of every individual being able to access the services they need without financial hardship. However, in many African countries, the concept of UHC often excludes comprehensive cancer care, leaving millions to face the devastating costs of treatment on their own. This exclusion creates a silent crisis: patients with cancer unable to afford care are often diagnosed late, succumb to preventable&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;Promoting data, research, and regional collaboration&lt;/h2&gt;Cancer registries are often the unsung heroes of effective health systems. They provide crucial data to track incidence rates, evaluate treatment outcomes, and guide policy decisions. Yet many African countries do not have comprehensive registries, leaving a gap in their cancer response.Embassies could support the creation of these registries by funding training programmes for health-care workers and ensuring that registry systems are integrated into national health strategies. The absence of&lt;/section&gt;&lt;/section&gt;&lt;section&gt;&lt;section&gt;&lt;h2&gt;A new diplomacy for global health&lt;/h2&gt;The role of embassies in cancer care must evolve. Although Rotary runs, radiotherapy centres, and awareness campaigns are valuable, they remain insufficient. By leveraging their diplomatic power, embassies can push for the systemic reforms needed to transform cancer care from a privilege to a right.Embassies, with their unique ability t","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study","authors":"Vikas Gupta, Michael J Satlin, Kalvin C Yu, Yehoda Martei, Lillian Sung, Lars F Westblade, Scott Howard, ChinEn Ai, Diane C Flayhart","doi":"10.1016/s1470-2045(25)00128-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00128-7","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Infections are the second leading cause of death in patients with cancer and are often caused by resistant bacteria. However, the frequency of antimicrobial resistance (AMR) in outpatients with cancer is not well understood. We aimed to compare the frequency of AMR bacterial pathogens in outpatients with and without cancer.&lt;h3&gt;Methods&lt;/h3&gt;This retrospective cohort study evaluated antimicrobial susceptibility of bacteria isolated from adults (aged ≥18 years) with and without cancer seeking care in 198 outpatient health-care settings in the USA. Data were collected using the BD Insights Research Database. Patients who were not prescribed cancer medications or not admitted to an inpatient cancer unit in the predefined period were categorised as patients without cancer. Patients were included in the cancer cohort if they received medication solely or sometimes indicated for cancer. Data on gender and race or ethnicity were not collected. Non-duplicate and non-contaminant pathogens collected from various samples (ie, blood, intra-abdominal, respiratory, urine, skin or wound, and other) in outpatients were used to assess the coprimary outcomes: overall and source-specific proportions of non-susceptible pathogen isolates with corresponding AMR odds ratios (ORs); and rates of AMR pathogens per 1000 isolates with corresponding AMR incidence rate ratio (IRR) in patients with and without cancer.&lt;h3&gt;Findings&lt;/h3&gt;Data were collected between April 1, 2018, and Dec 31, 2022. 53 006 (3·2%) of 1 655 594 pathogens identified were from 27 421 patients with cancer and 1 602 588 (96·8%) were from 928 128 patients without cancer. For &lt;em&gt;Pseudomonas aeruginosa&lt;/em&gt;, carbapenem non-susceptibility was higher in pathogen isolates from patients with cancer (816 [14·4%] of 5683) than patients without cancer (10 709 [11·3%] 94 419; OR 1·22 [95% CI 1·13–1·32]). For Enterobacterales, fluoroquinolone non-susceptibility was higher in pathogen isolates from patients with cancer (8662 [28·0%] of 30 867) than patients without cancer (238 479 [21·8%] of 1 095 996; OR 1·44 [1·40–1·47]), as was carbapenem non-susceptibility (472 [1·5%] of 30 867 &lt;em&gt;vs&lt;/em&gt; 9165 [0·8%] of 1 095 996; OR 1·89 [1·72–2·07]), multidrug-resistant pathogens (2672 [8·7%] of 30 867 &lt;em&gt;vs&lt;/em&gt; 48 962 [4·5%] of 1 095 996; OR 2·03 [1·95–2·11]), and extended-spectrum β-lactamase producers (4343 [16·5%] of 26 327 &lt;em&gt;vs&lt;/em&gt; 93 977 [9·4%] of 996 853; OR 1·96 [1·90–2·03]). For &lt;em&gt;Staphylococcus aureus&lt;/em&gt;, meticillin resistance was higher in pathogen isolates from patients with cancer (4747 [53·0%] of 8959) than patients without cancer (129 291 [48·3%] of 267 520; OR 1·20 [1·15–1·25]). For &lt;em&gt;Enterococcus&lt;/em&gt; spp, vancomycin resistance was higher in pathogen isolates from patients with cancer (1329 [18·6%] of 7145) than patients without cancer (12 333 [9·1%] of 135 772]; ORR 2·20 [2·06–2·34). The rates and corresponding IRRs of AMR pathogens per 1000 isolates was also higher in patients with","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group","authors":"Maj-Britt Jensen, Emma Torpe, Zoë Teunissen, Gry Taarnhøj, Eva Brix, Ann Knoop, Sophie Yammeni, Frede Donskov, Bent Ejlertsen","doi":"10.1016/s1470-2045(25)00085-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00085-3","url":null,"abstract":"<h3>Background</h3>Clinical prediction models are increasingly used to guide treatment in patients with early breast cancer. The Danish Breast Cancer Group (DBCG) has developed a prognostic standard mortality rate index (PSI) for prediction of excess mortality based on 5 years of endocrine therapy. In this study, we aimed to evaluate the clinical utility of the PSI.<h3>Methods</h3>In this nationwide, prospective cohort study, we included postmenopausal Danish women aged 50 years or older with invasive oestrogen receptor-positive and HER2-negative resected breast cancer registered in the DBCG clinical database (close to all Danish women newly diagnosed with invasive breast cancer are registered in the national database). All participants were assigned a PSI category. Patients in the PSI 1 category were recommended 5 years of endocrine therapy; patients in PSI 2, 3, or 4 category were recommended endocrine therapy plus adjuvant chemotherapy according to Danish national guidelines. The primary endpoint was standard mortality ratio. Univariable and multivariable analyses for standard mortality ratio, overall survival, and recurrence-free survival were performed applying Kaplan–Meier, cumulative incidence, Poisson regression, and Fine–Gray subdistribution hazards model.<h3>Findings</h3>25 027 women diagnosed with breast cancer between Aug 1, 2013, and Dec 31, 2018, and registered with the DBCG clinical database were identified. 8921 of those registered were eligible, assigned a PSI category (6704 [75%] PSI 1, 1300 [15%] PSI 2, 745 [8%] PSI 3, and 172 [2%] PSI 4), and included in the study. 8514 [96%] of 8830 women initiated endocrine therapy and 91 had an unknown therapy status. Adherence at 4·5 years was 67·8% (66·6–69·0) in the PSI 1 group and 72·3% (70·5–74·3) in the PSI 2–4 groups. Crude standard mortality ratio was 0·89 (95% CI 0·85–0·95) with PSI 1, 1·71 (95% CI 1·47–1·97) with PSI 2, and 2·39 (95% CI 1·99–2·88) with PSI 3–4. Compared with patients who completed adjuvant therapy with PSI 1, relative risk (RR) for excess mortality was 1·33 (95% CI 1·01–1·76) for patients with PSI 2 whereas patients with PSI 3–4 retained an excess mortality (RR 2·31, 95% CI 1·74–3·05) even with completed therapy.<h3>Interpretation</h3>These data validate the clinical use of the PSI tool for risk adapted treatment allocation. In patients with PSI 1, the omission of chemotherapy was not associated with excess mortality overall and a distinct better outcome was seen in patients with completed endocrine therapy versus those who had not completed. With completed adjuvant therapy, excess mortality was low for patients with PSI 2, whereas patients with PSI 3–4 had high excess mortality, potentially warranting intensified treatment and requiring further investigation.<h3>Funding</h3>None.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis on SBRT and ablation for localised RCC – Authors' reply","authors":"Ryan S Huang, Ronald Chow, Srinivas Raman","doi":"10.1016/s1470-2045(25)00212-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00212-8","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}